Porcilis ColiClos
vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs
Table of contents
Overview
This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).
Authorisation details
Product details | |
---|---|
Name |
Porcilis ColiClos
|
Agency product number |
EMEA/V/C/002011
|
Active substance |
Clostridium perfringens type C / Escherichia coli F4ab / E. coli F4ac / E. coli F5 / E. coli F6 / E. coli LT
|
International non-proprietary name (INN) or common name |
vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs
|
Species |
Pigs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AB08
|
Publication details | |
---|---|
Marketing-authorisation holder |
Intervet International BV
|
Revision |
5
|
Date of issue of marketing authorisation valid throughout the European Union |
14/06/2012
|
Contact address |
Wim de Körverstraat 35
5831 AN Boxmeer Netherlands |
Product information
19/06/2020 Porcilis ColiClos - EMEA/V/C/002011 - IAIN/0011/G
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Therapeutic indication
For the passive immunisation of progeny by active immunisation of sows and gilts to reduce mortality and clinical signs during the first days of life, caused by those Escherichia coli strains which express the adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P) and caused by Clostridium perfringens type C.